Oxford Gene Technology Appoints Research and Development Director
News Jan 06, 2006
Oxford Gene Technology has announced the appointment of Dr John Anson as Research and Development Director.
John joins OGT after 16 years at Amersham Biosciences/GE Healthcare where he held positions as Head of Product Development, Lead Discovery, Cardiff; Vice President for Pharmacogenomics; Vice President for Business Development and Programme Manager.
John brings to OGT a wide experience of product development for the life science market, having led teams responsible for the launch of several industry-leading products, including the IN Cell analyser for automated cell-based assays and LEADseeker for in vitro drug screening.
Prior to Amersham Biosciences, John carried out Post Doctorate research at PHLS Centre for Applied Microbiology and Research, Porton Down, and holds a PhD in Bacterial Genetics from Cranfield University and a BSc (Hons) in Microbiology from the University of Kent.
"I am looking forward to joining OGT and working with its scientists to develop products and services for commercialisation into the life science and molecular medicine markets," said John.
Dr Mike Evans, OGT's Chief Executive, said, "I am delighted to welcome John to OGT."
"With his track record and experience in research, product development and management of collaborations, John will make a major contribution to OGT's development of products and services for the life science and molecular medicine markets."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.